Drug Profile
Darbepoetin alfa biosimilar - Nanogen Biopharmaceutical
Alternative Names: Darbepoetin - Nanogen; NNG-DEPO; STIMUSLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Anaemia
Most Recent Events
- 25 Mar 2021 Nanogen Biopharmaceutical plans to launch Darbepoetin alfa biosimilar in 2021
- 08 Aug 2019 Phase III clinical trials in Anaemia in Vietnam (SC) (Nanogen Biopharmaceutical pipeline, March 2021) (NCT05585645)
- 20 Mar 2014 Early research in Anaemia in Vietnam (SC)